SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison (MAIC) to Explore the Impact of Subsequent Therapy

H Wheat,A Hatswell,P Christopoulos,S Ekman,F Guisier,E Hook,H Vioix

doi:10.1016/j.jval.2023.09.2931

SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison (MAIC) to Explore the Impact of Subsequent Therapy

H Wheat, A Hatswell + Show 5 more

https://doi.org/10.1016/j.jval.2023.09.2931

Copy DOI

Journal: Value in Health

Publication Date: Dec 1, 2023

Affiliation: University Hospital Heidelberg

#Matching-Adjusted Indirect Comparison #MET Exon 14 + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison (MAIC) to Explore the Impact of Subsequent Therapy

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Value in Health

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.